Ki-67的表达与胃癌患者临床病理特征及预后的关系  

Association of Ki- 67 expression with clinicopathologic features and prognosis in gastric cancer

作　　者：黄天臣[1] 肖建安[1] 王青兵[1] 王雁军[1] 张勇[1] 白东晓[1] 邱新光[2] 

机构地区：[1]河南安阳市肿瘤医院外四科,安阳455000 [2]郑州大学第一附属医院普通外科,郑州450052

出　　处：《河南外科学杂志》2016年第3期15-18,共4页Henan Journal of Surgery

摘　　要：目的探讨Ki-67在胃癌组织中的表达及其临床意义。方法采用免疫组化技术,检测326例胃腺癌组织及相应326例正常胃黏膜组织中Ki-67蛋白的表达情况。采用半定量RT-PCR实验检测,随机选取10例胃腺癌组织和相对应的正常胃黏膜组织中Ki-67mRNA的表达情况,应用χ2检验、Kaplan-Meier生存分析及COX回归分析与患者临床病理特征及预后的关系。结果胃癌组织中Ki-67蛋白和mRNA明显高于正常胃黏膜组织(P<0.05)。Kaplan-Meier生存分析显示Ki-67蛋白表达与胃癌患者的预后密切相关(χ2=8.086,P=0.005),COX回归分析显示Ki-67为胃癌患者预后的独立因素(P=0.002)。结论 Ki-67的表达与胃癌预后密切相关,为胃癌患者预后的独立因素。Objective To investigate the Ki- 67 expression and its clinical significance in gastric cancer. Methods The expressions of Ki- 67 protein in 326 adenocarcinoma of gastric structures and in the corresponding 326 normal gastric mucosa structures will be tested by applying Immunohistochemical Technique. The expressions of Ki- 67 mRNA in 10 random chosen cases of adenocarcinoma of gastric structures and its corresponding normal gastric mucosa structures will be tested by semi- quantitative RT- PCR. The associationof Ki- 67 expression with clinicopathologic features and prognosis in gastric cancer patients were analyzed with various statistical methods,such as χ^2- test,Kaplan-Meier method and COX proportional hazard model. Results Ki- 67 protein and Ki- 67 mRNA in the gastric cancer structure clearly is more than that in normal gastric mucosa structure（ P〈0. 05）. The gastric cancer patient＇s survival rate with high expression of Ki- 67 is dramatically lower than that with low expression of Ki- 67. The expression of Ki- 67 is closely related to stomach cancer patient＇s prognosis（ χ^2=8. 086,P = 0. 005）. The result of COX proportional hazard model shows that Ki- 67 is the independent prognostic factor of stomach cancer patient（ P = 0. 002）. Conclusion The expression of Ki- 67 is closely related to the prognosis; Ki- 67 is the independent prognostic factor of gastric cancer.

关 键 词：胃癌 KI-67 临床病理特征 预后 

分 类 号：R392.31[医药卫生—免疫学]